Nov 23, 2015 (ACCESSWIRE via COMTEX) -- LAS VEGAS, NV / ACCESSWIRE / November 23, 2015 / According to Global Analyst Reports, the world market for colorectal cancer is expected to reach $8.8 billion by 2020 and the global pancreatic cancer market is projected to exceed $1.2 billion by 2015.
Propanc Health Group Corporation (PPCH) is developing a drug that could take a major slice of both markets. PPCH is developing new and proprietary treatments for cancer patients suffering from pancreatic and colorectal cancers.
In recent preclinical animal efficacy studies, PPCH has shown significant tumor growth inhibition in pancreatic and ovarian cancers for PRP. The results from these studies were also used to file a new patent specifying a new target efficacious dose range for future human studies.
"We are thrilled with the results and believe it now paves the way for scientific advice meetings with regulatory agencies to determine the development pathway for human studies," said James Nathanielsz, Propanc's Chief Executive Officer, "As a result of achieving this significant milestone, we are convinced PRP, which is a combination of two proenzymes, trypsinogen and chymotrypsinogen, could become a breakthrough treatment in the fight against aggressive tumors like pancreatic and ovarian cancers. In fact, most common solid tumors."
In the pancreatic cancer study, Pan-02 mouse pancreatic tumor cells were orthotopically inoculated (i.e. grafted into its normal place in the body) into immune competent (C57BL/6) mice.Treatment with PRP injected once daily commenced nine days post inoculation, identified as Day 0. At Day 26, significant (p≤0.05) reduction in mean tumor weight was observed, 86% inhibition at the efficacious dose compared to the vehicle control.
Adding this new patent to their already impressive treatment increases the potential of the company 10 fold. However, all this potential doesn't matter without the funding to fulfill it, which is not a problem for PPCH:
Secured Financing
PPCH just secured a $4mm dollar financing. For many biotechs the biggest hurdle in their growth is securing working capital throughout the trial phases. Propanc has continued to secure financing at favorable terms while working it's way through the trial phases.
The hope is that this financing will finally bring them to the all important human trials. "I firmly believe this financing puts the Company in a position to rapidly progress PRP towards human trials," said James Nathanielsz, Propanc's Chief Executive Officer.
Possible Uplisting
After completing this important financing for the Company, management will now focus its attention towards up-listing onto a National Exchange, most likely in 2016.
"We believe that up-listing onto a top tier Exchange like the NASDAQ is an important step for the Company to realize value and become a recognized player in the biotech sector. Nevertheless, we will continue to focus on achieving our near term milestones and remain hopeful that market conditions will present an opportunity for up-listing, which shareholders will view positively and welcome as part of the Company's overall growth strategy."
A good sign that PPCH will be able to uplist is their recent incl
